Effect of Adding Folic Acid on Lipid Parameters in Population With Dyslipidemias
Primary Purpose
Dyslipidemias
Status
Unknown status
Phase
Not Applicable
Locations
Pakistan
Study Type
Interventional
Intervention
Folic Acid
Placebo
Sponsored by
About this trial
This is an interventional treatment trial for Dyslipidemias focused on measuring Folic Acid, Dyslipidemias, Hyperlipidemia
Eligibility Criteria
Inclusion Criteria:
1. Otherwise, healthy individuals of either sex with any of the following characteristics will be including in the study.
- Serum cholesterol >200mg/dl
- Serum triglyceride > 150mg/dl
- Serum LDL >100mg/dl
- Serum HDL < 40mg/dl
Exclusion Criteria:
- Patients who have any clinically significant or unstable medical or psychiatric illnesses.
- Patients with CKD, diabetes mellitus, coronary artery disease, with history of stroke, myocardial infarction or any chronic illnesses.
- Substance abuse such as alcoholism excluded by taking history.
- Patients who are pregnant are excluded by taking history and urine dipstick test where applicable.
- Patient who are treated with any investigational drug within last 60 days.
- Patients who are taking a statin or any other lipid lowering drug.
Sites / Locations
- Shaheed Zulfiqar Ali Bhutto Medical University, Pakistan Institute of Medical Sciences Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Group A
Group B
Arm Description
Folic acid 1mg daily will be given to the participants of Group A.
A Placebo (a sugar pill) will be given to the participants of the Group B.
Outcomes
Primary Outcome Measures
LDL
mg/dL
HDL
mg/dL
Triglycerides
mg/dL
Total Cholesterol
mg/dL
Secondary Outcome Measures
Full Information
NCT ID
NCT03674333
First Posted
September 14, 2018
Last Updated
September 14, 2018
Sponsor
Shaheed Zulfiqar Ali Bhutto Medical University
1. Study Identification
Unique Protocol Identification Number
NCT03674333
Brief Title
Effect of Adding Folic Acid on Lipid Parameters in Population With Dyslipidemias
Official Title
Effect of Adding Folic Acid on Lipid Parameters in Population With Dyslipidemias
Study Type
Interventional
2. Study Status
Record Verification Date
September 2018
Overall Recruitment Status
Unknown status
Study Start Date
September 24, 2018 (Anticipated)
Primary Completion Date
February 28, 2019 (Anticipated)
Study Completion Date
March 15, 2019 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Shaheed Zulfiqar Ali Bhutto Medical University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Background: Homocysteinemia is associated with increased risk of stroke, dyslipidemias, dementia, peripheral vascular disease and coronary artery disease. folic acid is involved in the metabolism of homocysteine. Folic acid supplementation helps to reduce homocysteine levels and lowering of homocysteine may cause improvement in serum lipid profile. In this study we will assess the effect of folic acid supplementation for 6 weeks, on lipid parameter in patients who have dyslipidemia.
Methods: It is a placebo controlled randomized trial, consisting of two groups, Group A (n=34) and Group B (n=34). Group A (intervention group) will be given Folic acid supplements and the second group will be given a placebo. After 6 weeks changes in lipid parameters, will be measured in both groups.
Discussion: Folic acid is water soluble vitamin also known as vitamin B-9. Folic acid works as co-factor in many biochemical enzymatic reactions. Homocysteine metabolism also requires folic acid, homocysteinemia may worsen renal function, lipid parameter, accelerate atherosclerosis, angiopathies, and progression of dementia, also increase the risk of stroke and coronary artery disease. In this study, Group A (treatment Group) will be given folic acid supplementation while the Group B (Placebo Group) will be given placebo and at the end of 6 weeks, HDL, LDL, Triglycerides and serum cholesterol levels will be measured and compared with the pre-treatment levels. If Post-treatment group shows significant decrease in serum LDL, total cholesterol, triglycerides and increase in HDL then Folic acid supplementation may be routinely recommended for patient with dyslipidemias.
Detailed Description
Hyperlipidemia, increases the risk of stroke, hypertension, coronary artery disease and other associated disorders. World-wide about one-third of coronary artery disease is attributed high cholesterol. Overall it has been estimated that elevated blood cholesterol causes 26 million deaths (4.5% of the total deaths) world-wide. Hyperlipidemias is a major cause of morbidity in both developed and developing countries as a risk factor for stroke and coronary artery disease. The prevalence of raised total cholesterol increased noticeably according to the income level of the country. In low income countries around a quarter of adults had raised total cholesterol, in lower middle income countries this rose to around a third of the population for both sexes. In high-income countries, over 50% of adults had raised total cholesterol; more than double the level of the low-income countries.
Homocysteine, on the other hand, is a sulfur amino acid, which is metabolized by two pathways, either it is re-methylated to methionine or it undergoes trans-sulfuration to cystathionine which is eventually converted into cysteine, an amino acid. Folic acid is involved in remethylation of homocysteine to methionine. Thus, folic acid supplementation may enhance the metabolism of homocysteine level and thereby may decrease its level in blood. Homocysteine in blood is termed as homocysteinemia. Homocysteinemia is associated with dyslipidemias, increased risk of atherosclerosis, micro-angiopathies, coronary artery disease, stroke, dementia and also found to be associated with suppressed immunity. Supplementation with folic acid may lower homocysteine level by accelerating its metabolism to methionine. In this study investigators will be assessing the effect of folate supplementation on the lipid profile, particularly on the blood levels of HDL, LDL, Triglycerides and total cholesterol. The HDL has cardio-protective effect, while on the other hand, the higher level of LDL, total cholesterol and triglycerides may accelerate atherosclerosis, angiopathies and increases the risk of stroke and heart diseases.
Research question: Does addition of folic acid supplementation decrease LDL, total cholesterol, triglycerides and increase HDL in patients with dyslipidemias.
OBJECTIVE:
To assess the effect of folic acid supplementation on HDL, LDL, total cholesterol and triglycerides in patients with dyslipidemias.
HYPOTHESIS Addition of folic acid supplementation will improve lipid parameters (HDL, total cholesterol, triglycerides & LDL) in patients with dyslipidemias.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Dyslipidemias
Keywords
Folic Acid, Dyslipidemias, Hyperlipidemia
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Group A receives Folic Acid and Group B receives Placebo.
Masking
Participant
Masking Description
Participants of both the groups will be unaware of whether they received placebo or folic acid.
Allocation
Randomized
Enrollment
68 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Group A
Arm Type
Experimental
Arm Description
Folic acid 1mg daily will be given to the participants of Group A.
Arm Title
Group B
Arm Type
Placebo Comparator
Arm Description
A Placebo (a sugar pill) will be given to the participants of the Group B.
Intervention Type
Dietary Supplement
Intervention Name(s)
Folic Acid
Intervention Description
Folic acid is a water soluble vitamin, required for various biological functions in human body, including metabolism of homocysteine.
Intervention Type
Other
Intervention Name(s)
Placebo
Intervention Description
Placebo - a sugar pill
Primary Outcome Measure Information:
Title
LDL
Description
mg/dL
Time Frame
6 weeks
Title
HDL
Description
mg/dL
Time Frame
6 weeks
Title
Triglycerides
Description
mg/dL
Time Frame
6 weeks
Title
Total Cholesterol
Description
mg/dL
Time Frame
6 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
1. Otherwise, healthy individuals of either sex with any of the following characteristics will be including in the study.
Serum cholesterol >200mg/dl
Serum triglyceride > 150mg/dl
Serum LDL >100mg/dl
Serum HDL < 40mg/dl
Exclusion Criteria:
Patients who have any clinically significant or unstable medical or psychiatric illnesses.
Patients with CKD, diabetes mellitus, coronary artery disease, with history of stroke, myocardial infarction or any chronic illnesses.
Substance abuse such as alcoholism excluded by taking history.
Patients who are pregnant are excluded by taking history and urine dipstick test where applicable.
Patient who are treated with any investigational drug within last 60 days.
Patients who are taking a statin or any other lipid lowering drug.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Adil Ramzan, MD
Phone
+923336671671
Email
adilramzan@gmail.com
First Name & Middle Initial & Last Name or Official Title & Degree
M Ali Arif, FRCP
Email
mohammad_ali_arif@hotmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Adil Ramzan, MD
Organizational Affiliation
Shaheed Zulfiqar Ali Bhutto Medical University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Shaheed Zulfiqar Ali Bhutto Medical University, Pakistan Institute of Medical Sciences Hospital
City
Islamabad
ZIP/Postal Code
44000
Country
Pakistan
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Fibhaa Syed, FCPS, MRCP
Phone
923335300002
Email
Fibhaasyed@gmail.com
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Plan Description
Individual participants data will be available. Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures and appendices) will be shared to the researchers who provide a methodologically sound proposal to the primary investigator (Dr. Adil Ramzan).
IPD Sharing Time Frame
Beginning 3 months and ending 5 years following publication of the article.
IPD Sharing Access Criteria
Proposal should be directed to "adilramzan@gmail.com". To access data, data requestors will need to sign a data access agreement. Data are available for 5 years at 3rd party website.
IPD Sharing URL
http://www.dradilramzan.com
Citations:
PubMed Identifier
20814827
Citation
Blom HJ, Smulders Y. Overview of homocysteine and folate metabolism. With special references to cardiovascular disease and neural tube defects. J Inherit Metab Dis. 2011 Feb;34(1):75-81. doi: 10.1007/s10545-010-9177-4. Epub 2010 Sep 4.
Results Reference
background
PubMed Identifier
24002360
Citation
Mierzecki A, Kloda K, Bukowska H, Chelstowski K, Makarewicz-Wujec M, Kozlowska-Wojciechowska M. Association between low-dose folic acid supplementation and blood lipids concentrations in male and female subjects with atherosclerosis risk factors. Med Sci Monit. 2013 Sep 4;19:733-9. doi: 10.12659/MSM.889087.
Results Reference
background
PubMed Identifier
28552882
Citation
Baszczuk A, Thielemann A, Musialik K, Kopczynski J, Bielawska L, Dzumak A, Kopczynski Z, Wysocka E. The Impact of Supplementation with Folic Acid on Homocysteine Concentration and Selected Lipoprotein Parameters in Patients with Primary Hypertension. J Nutr Sci Vitaminol (Tokyo). 2017;63(2):96-103. doi: 10.3177/jnsv.63.96.
Results Reference
background
Learn more about this trial
Effect of Adding Folic Acid on Lipid Parameters in Population With Dyslipidemias
We'll reach out to this number within 24 hrs